Endpoints for lymphatic filariasis programs

• Published in: Emerging infectious diseases Vol. 13; no. 4; pp. 608 - 610
• Main Authors: Grady, Caroline A, de Rochars, Madsen Beau, Direny, Abdel N, Orelus, Jean Nicolas, Wendt, Joyanna, Radday, Jeanne, Mathieu, Els, Roberts, Jacquelin M, Streit, Thomas G, Addiss, David G, Lammie, Patrick J
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01.04.2007; Centers for Disease Control and Prevention
• Subjects: Albendazole - administration & dosage; Albendazole - adverse effects; Albendazole - therapeutic use; Animals; diethylcarbamazine (DEC); Diethylcarbamazine - administration & dosage; Diethylcarbamazine - adverse effects; Diethylcarbamazine - therapeutic use; Disease transmission; Dispatch; Drug Therapy, Combination; Elephantiasis, Filarial - drug therapy; Elephantiasis, Filarial - epidemiology; Elephantiasis, Filarial - parasitology; Elephantiasis, Filarial - prevention & control; elimination; Filariasis; Filaricides - administration & dosage; Filaricides - adverse effects; Filaricides - therapeutic use; Government Programs - standards; Haiti - epidemiology; Health aspects; Humans; Infection; lymphatic filariasis; mass drug administration; microfilaremia; Microfilariae - drug effects; Mosquitoes; Prevalence; Program Evaluation; Wuchereria bancrofti; Wuchereria bancrofti - drug effects; Haiti
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid1304.061063

In 2000, annual mass administration of diethlycarbamazine and albendazole began in Leogane Commune, Haiti, to interrupt transmission of lymphatic filariasis (LF). After 5 years of treatment, microfilaremia, antigenemia, and mosquito infection rates were significantly reduced, but LF transmission was not interrupted. These finding have implications for other LF elimination programs.